- Title
- Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma: A Multipart, Open-Label, Phase 1b Trial
- Creators
- Paolo Strati - The University of Texas MD Anderson Cancer CenterBeth Christian - The Ohio State UniversityPeter Martin - NewYork–Presbyterian HospitalBecky Champion - 4Norton Cancer Institute, Louisville, KYMorton Coleman - Cornell UniversityRichy Agajanian - Oncology Institute of Hope and InnovationSonali M. Smith - University of Chicago Medical CenterParameswaran Venugopal - Rush University Medical CenterIzidore S. Lossos - University of MiamiRobert Kridel - Princess Margaret Cancer CentreRoser Calvo - AstraZenecaKara Higgins - AstraZenecaDeborah M. Stephens - Huntsman Cancer Institute
- Publication Details
- Blood, Vol.140(Supplement 1), pp.3606-3608
- Publisher
- Elsevier Inc
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- Record Identifier
- 991031786516002976
Journal article
Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma: A Multipart, Open-Label, Phase 1b Trial
Blood, Vol.140(Supplement 1), pp.3606-3608
2022-11-15
Metrics
21 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.130 Lymphomas
- 1.130.132 Lymphoma
- Web Of Science research areas
- Hematology
- ESI research areas
- Clinical Medicine
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites